Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

This study has been completed.
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by (Responsible Party):
Pfizer Identifier:
First received: August 13, 2009
Last updated: November 30, 2015
Last verified: November 2015
The purpose of this study is to assess the safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, in subjects with mild to moderate Alzheimer's disease in Japan.

Condition Intervention Phase
Alzheimer's Disease
Biological: ACC-001
Other: QS-21
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence of Treatment-emergent Adverse Events (AEs) by Severity [ Time Frame: Baseline up to 24 months ]
    Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)

  • Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data [ Time Frame: Baseline up to 24 months ]
    Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.

  • Number of Participants With Abnormalities in Neurological Examination [ Time Frame: Baseline up to 24 months ]
    Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.

Secondary Outcome Measures:
  • Anti-a-beta IgG Titer at Specified Visits [ Time Frame: Baseline up to 24 months ]
    Geometric mean of anti-a-beta IgG titer from pre-study through Week 104

  • Anti-a-beta IgM Titer at Specified Visits [ Time Frame: Baseline up to 24 months ]
    Geotmetric mean of anti-a-beta IgM titer from pre-study through Week 104

Other Outcome Measures:
  • The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 12, 26, 52, 78 and 104. [ Time Frame: Baseline up to 24 months ]
    The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11. Total score ranges from 0 to 70 points, with higher scores indicating a greater degree of impairment.

  • The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 12, 26, 52,78 and 104. [ Time Frame: Baseline up to 24 months ]

    The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living.

    A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.

  • The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 12, 26, 52 and 78. [ Time Frame: Baseline up to 24 months ]
    The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit - y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants' observed baseline scores in the study.

  • The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 4, 8, 12, 16, 26, 30, 40, 52, 78 and 104. [ Time Frame: Baseline up to 24 months ]
    The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.

Enrollment: 32
Study Start Date: August 2009
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ACC-001 + QS-21
Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
Biological: ACC-001
IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
Other: QS-21
IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
Placebo Comparator: QS-21
Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
Other: QS-21
IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of mild to moderate Alzheimer's Disease
  • Mini-Mental State Examination (MMSE) 16-26

Exclusion Criteria:

  • Significant Neurological Disease other than Alzheimer's disease
  • Major psychiatric disorder
  • Clinically significant systemic illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00959192

Meitetsu Hospital
Aichi, Japan, 451-8511
Ibaraki Prefectural Central Hospital
Ibaraki, Japan, 309-1793
Shonan Atsugi Hospital
Kanagawa, Japan, 243-8551
Kitasato University East Hospital
Kanagawa, Japan, 252-0380
Tazuke Kofukai Medical Research Institute Kitano Hospital
Osaka, Japan, 530-8480
The Jikei University School of medicine
Tokyo, Japan, 105-8471
Juntendo University Hospital
Tokyo, Japan, 113-8431
Juntendo Tokyo Koto Geriatric Medical Center
Tokyo, Japan, 136-0075
Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache
Tokyo, Japan, 158-8531
Sponsors and Collaborators
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00959192     History of Changes
Other Study ID Numbers: 3134K1-2206
B2571009 ( Other Identifier: Alias Study Number )
Study First Received: August 13, 2009
Results First Received: May 9, 2014
Last Updated: November 30, 2015

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
QS 21
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017